Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer

Providence, RI, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases such as chronic obstructive pulmonary disease (COPD). This research demonstrates for the first time the complex ways that CHI3L1 inhibits macrophage phagocytosis by stimulating two key phagocytosis checkpoint pathways. The paper notes, "This inhibition of innate immune responses such as phagocytosis provides a mechanistic explanation for the ability of CHI3L1 to stimulate immune checkpoint inhibitors (ICPs) and inhibit essential adaptive immune responses in cancer and COPD. The ability of CHI3L1 to simultaneously inhibit innate immune responses, stimulate ICPs, inhibit T cell costimulation, and regulate a number of other oncogenic and inflammation pathways suggests that CHI3L1-targeted therapeutics are promising interventions in cancer, COPD, and other disorders." Dr. Elias' research has shown that the inhibition of CHI3L1 diminishes natural adaptive immune responses and reduces cancer growth in vivo in standard and humanized mouse models.

Ocean Biomedical's monoclonal antibody is one piece of a unique oncology platform that is working to build multiple approaches to activating natural cancer immune responses by suppressing Chi3L1, with potential for broad application. The patent allowance has been granted for Prostate Cancer, Colon Cancer, Rectal Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.